Expert consensus on the persistence of biological treatments in moderate-to-severe psoriasis
Fecha
2019
Título de la revista
ISSN de la revista
Título del volumen
Editor
Wiley
Resumen
Background Treatment persistence is becoming a useful measure to evaluate long-term effectiveness and safety of
biological therapies in real-world settings.
Objective The main objective of this study was to explore the scientific opinion of a panel of dermatologists and hospi tal pharmacists to reach a consensus about the impact, causes, and best strategies and interventions that might be
associated with improved drug persistence in patients with psoriasis in Spain.
Methods This research was conducted using a modified Delphi method organized in two rounds and involving a panel
of 90 dermatologists and 34 hospital pharmacists. A questionnaire of 70 items was developed. The items proposed to
reach a consensus included topics such as definitions and measures in the treatment of psoriasis, analysis of treatment
persistence, factors that may influence treatment persistence, impact of treatment persistence and economic cost of
treatment.
Results Dermatologists reached a consensus on 77.1% of the items proposed, and hospital pharmacists reached a
consensus on 71.4%. Both groups agreed that it is important to use standardized measures in the evaluation of treat ment maintenance over time. Dermatologists agreed that treatment survival, persistence and retention are synonymous,
but hospital pharmacists considered only treatment persistence as a valid term. In addition, panelists agreed that drug
persistence is an indicator of success in the treatment of psoriasis that may be influenced by a drug’s effectiveness and
safety profile, as well as by patient satisfaction. They agreed that the different causes of treatment discontinuation
should be considered in Kaplan–Meier analysis of treatment persistence. Moreover, treatment persistence was agreed
to decrease the cost of therapy.
Conclusion This Delphi consensus highlights the different perspectives of dermatologists and hospital pharmacists
regarding the interpretation of treatment persistence, and the challenge of harmonizing the results obtaine
Descripción
Palabras clave
Citación
JEADV 2019, 33, 1214–1223